Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I-II, open-label trial

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2206-2214

  Vollmer, Timothy ^a   Henney III, Herbert R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 aminopyridine; fampridine SR; multiple sclerosis; pharmacokinetics

Indexed keywords

4 AMINOPYRIDINE;

ADULT; AGE DISTRIBUTION; AMBLYOPIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATAXIA; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; HUMAN; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QT INTERVAL; SEX RATIO; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

4-AMINOPYRIDINE; AGED; AREA UNDER CURVE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; QUALITY CONTROL; SEX CHARACTERISTICS; TANDEM MASS SPECTROMETRY;

EID: 71549141975     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.008     Document Type: Article

References (39)

1. Judge S.I., and Bever Jr. C.T. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 111 (2006) 224-259
2. Lundh H., and Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol. 42 (1977) 411-412
3. Targ E.F., and Kocsis J.D. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 328 (1985) 358-361
4. Kirsch G.E., and Drewe J.A. Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J Gen Physiol. 102 (1993) 797-816
5. Shi R., and Blight A.R. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience. 77 (1997) 553-562
6. Hansebout R.R., Blight A.R., Fawcett S., and Reddy K. 4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients. J Neurotrauma. 10 (1993) 1-18
7. Potter P.J., Hayes K.C., Hsieh J.T., et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases. Spinal Cord. 36 (1998) 147-155
8. Segal J.L., Pathak M.S., Hernandez J.P., et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial. Pharmacotherapy. 19 (1999) 713-723
9. Segal J.L., Hayes K.C., Brunnemann S.R., et al. Absorption characteristics of sustained-release 4-aminopyridine (fam pridine SR) in patients with chronic spinal cord injury. J Clin Pharmacol. 40 (2000) 402-409
10. van der Bruggen M.A., Huisman H.B., Beckerman H., et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol. 248 (2001) 665-671
11. Cardenas D.D., Ditunno J., Graziani V., et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 45 (2007) 158-168
12. Polman C.H., Bertelsmann F.W., van Loenen A.C., and Koetsier J.C. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 51 (1994) 292-296
13. Schwid S.R., Petrie M.D., McDermott M.P., et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 48 (1997) 817-821
14. Goodman A.D., Cohen J.A., Cross A., et al. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 13 (2007) 357-368
15. Hayes K.C., Katz M.A., Devane J.G., et al. Pharmacokinetics of an immediaterelease oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol. 43 (2003) 379-385
16. Evenhuis J., Agoston S., Salt P.J., et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth. 53 (1981) 567-570
17. Uges D.R., Sohn Y.J., Greijdanus B., et al. 4-Aminopyridine kinetics. Clin Pharmacol Ther. 31 (1982) 587-593
18. Bever Jr. C.T., Young D., Anderson P.A., et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 44 (1994) 1054-1059
19. Spyker D.A., Lynch C., Shabanowitz J., and Sinn J.A. Poisoning with 4-aminopyridine: Report of three cases. Clin Toxicol. 16 (1980) 487-497
20. Stork C.M., and Hoffman R.S. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol. 32 (1994) 583-587
21. Pickett T.A., and Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med. 27 (1996) 382-385
22. Johnson N.C., and Morgan M.W. An unusual case of 4-aminopyridine toxicity. J Emerg Med. 30 (2006) 175-177
23. US Food and Drug Administration. Center for Drug Evaluation and Research. Report: 2006 limited FDA survey of compounded drug products. http://www.fda.gov/cder/pharmcomp/survey_2006.htm Accessed June 9, 2008
24. Burton J.M., Bell C.M., Walker S.E., and O'Connor P.W. 4-Aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology. 71 (2008) 1833-1834
25. Hayes K.C., Potter P.J., Hsieh J.T., et al. Pharmacokinetics and safety of multiple oral doses of sustainedrelease 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil. 85 (2004) 29-34
26. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 13 (1983) 227-231
27. Goodman A.D., Brown T.R., Cohen J.A., et al., Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 71 (2008) 1134-1141
28. Goodman A.D., Brown T.R., Krupp L.B., et al., Fampridine MS-F203 Investigators. Sustainedrelease oral fampridine in multiple sclerosis: A randomised, doubleblind, controlled trial. Lancet. 373 (2009) 732-738
29. Smeets J.W., and Kunst M.W. Severe poisoning by 4-aminopyridine in a body builder [in Dutch]. Ned Tijdschr Geneeskd. 139 (1995) 2667-2669
30. Ball A.P., Hopkinson R.B., Farrell I.D., et al. Human botulism caused by Clostridium botulinum type E: The Birmingham outbreak. QJ Med. 48 (1979) 473-491
31. Ritschell W.A. Handbook of Basic Pharmacokinetics-Including Clinical Applications. 4th ed. (1992), Drug Intelligence Publications, Hamilton, Ill
32. International Conference on Harmonisation. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf Accessed June 9, 2008
33. Glantz S.A. Primer of Biostatistics (1981), McGraw-Hill, New York, NY
34. Blight A.R., and Henney III H.R. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther. 31 (2009) 328-335
35. Smith W, Swan S, Marbury T, Henney HR III. Single-dose pharmacokinetics of 4-aminopyridine slow release in healthy volunteers and renally impaired adults. J Clin Pharmacol. In press.
36. Hayes K.C., Potter P.J., Hansebout R.R., et al. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin Neuropharmacol. 26 (2003) 185-192
37. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 23 (2001) 1296-1310
38. Boxenbaum H. Pharmacokinetics tricks and traps: Flip-flop models. J Pharm Pharm Sci. 1 (1998) 90-91
39. In: Burks J.S., and Johnson K.P. (Eds). Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation (2000), Demos, New York, NY